Cognitive behavioral group therapy vs phenelzine therapy for social phobia 12-week outcome

Richard G. Heimberg, Michael R. Liebowitz, Debra A Hope, Franklin R. Schneier, Craig S. Holt, Lawrence A. Welkowitz, Harlan R. Juster, Raphael Campeas, Monroe A. Bruch, Marylene Cloitre, Brian Fallon, Donald F. Klein

Research output: Contribution to journalArticle

432 Citations (Scopus)

Abstract

Background: This article presents results of the acute treatment phase of a 2-site study comparing cognitive behavioral group therapy (CBGT) and treatment with the monoamine oxidase inhibitor phenelzine sulfate for social phobia. Methods: One hundred thirty-three patients from 2 sites received 12 weeks of CBGT, phenelzine therapy, pill placebo administration, or educational-supportive group therapy (an attention-placebo treatment of equal credibility to CBGT). The 'allegiance effect,' ie, the tendency for treatments to seem most efficacious in settings of similar theoretical orientation and less efficacious in theoretically divergent settings, was also examined by comparing responses to the treatment conditions at both sites: 1 known for pharmacological treatment of anxiety disorders and the other for cognitive behavioral treatment. Results: After 12 weeks, phenelzine therapy and CBGT led to superior response rates and greater change on dimensional measures than did either control condition. However, response to phenelzine therapy was more evident after 6 weeks, and phenelzine therapy was also superior to CBGT after 12 weeks on some measures. There were few differences between sites, suggesting that these treatments can be efficacious at facilities with differing theoretical allegiances. Conclusions: After 12 weeks, both phenelzine therapy and CBGT were associated with marked positive response. Although phenelzine therapy was superior to CBGT on some measures, both were more efficacious than the control conditions. More extended cognitive behavioral treatment and the combination of modalities may enhance treatment effect.

Original languageEnglish (US)
Pages (from-to)1133-1141
Number of pages9
JournalArchives of general psychiatry
Volume55
Issue number12
DOIs
StatePublished - Dec 1998

Fingerprint

Phenelzine
Cognitive Therapy
Group Psychotherapy
Therapeutics
Social Phobia
Placebos
Monoamine Oxidase Inhibitors

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., ... Klein, D. F. (1998). Cognitive behavioral group therapy vs phenelzine therapy for social phobia 12-week outcome. Archives of general psychiatry, 55(12), 1133-1141. https://doi.org/10.1001/archpsyc.55.12.1133

Cognitive behavioral group therapy vs phenelzine therapy for social phobia 12-week outcome. / Heimberg, Richard G.; Liebowitz, Michael R.; Hope, Debra A; Schneier, Franklin R.; Holt, Craig S.; Welkowitz, Lawrence A.; Juster, Harlan R.; Campeas, Raphael; Bruch, Monroe A.; Cloitre, Marylene; Fallon, Brian; Klein, Donald F.

In: Archives of general psychiatry, Vol. 55, No. 12, 12.1998, p. 1133-1141.

Research output: Contribution to journalArticle

Heimberg, RG, Liebowitz, MR, Hope, DA, Schneier, FR, Holt, CS, Welkowitz, LA, Juster, HR, Campeas, R, Bruch, MA, Cloitre, M, Fallon, B & Klein, DF 1998, 'Cognitive behavioral group therapy vs phenelzine therapy for social phobia 12-week outcome', Archives of general psychiatry, vol. 55, no. 12, pp. 1133-1141. https://doi.org/10.1001/archpsyc.55.12.1133
Heimberg, Richard G. ; Liebowitz, Michael R. ; Hope, Debra A ; Schneier, Franklin R. ; Holt, Craig S. ; Welkowitz, Lawrence A. ; Juster, Harlan R. ; Campeas, Raphael ; Bruch, Monroe A. ; Cloitre, Marylene ; Fallon, Brian ; Klein, Donald F. / Cognitive behavioral group therapy vs phenelzine therapy for social phobia 12-week outcome. In: Archives of general psychiatry. 1998 ; Vol. 55, No. 12. pp. 1133-1141.
@article{1a1d307746814b0c8598678b13c83154,
title = "Cognitive behavioral group therapy vs phenelzine therapy for social phobia 12-week outcome",
abstract = "Background: This article presents results of the acute treatment phase of a 2-site study comparing cognitive behavioral group therapy (CBGT) and treatment with the monoamine oxidase inhibitor phenelzine sulfate for social phobia. Methods: One hundred thirty-three patients from 2 sites received 12 weeks of CBGT, phenelzine therapy, pill placebo administration, or educational-supportive group therapy (an attention-placebo treatment of equal credibility to CBGT). The 'allegiance effect,' ie, the tendency for treatments to seem most efficacious in settings of similar theoretical orientation and less efficacious in theoretically divergent settings, was also examined by comparing responses to the treatment conditions at both sites: 1 known for pharmacological treatment of anxiety disorders and the other for cognitive behavioral treatment. Results: After 12 weeks, phenelzine therapy and CBGT led to superior response rates and greater change on dimensional measures than did either control condition. However, response to phenelzine therapy was more evident after 6 weeks, and phenelzine therapy was also superior to CBGT after 12 weeks on some measures. There were few differences between sites, suggesting that these treatments can be efficacious at facilities with differing theoretical allegiances. Conclusions: After 12 weeks, both phenelzine therapy and CBGT were associated with marked positive response. Although phenelzine therapy was superior to CBGT on some measures, both were more efficacious than the control conditions. More extended cognitive behavioral treatment and the combination of modalities may enhance treatment effect.",
author = "Heimberg, {Richard G.} and Liebowitz, {Michael R.} and Hope, {Debra A} and Schneier, {Franklin R.} and Holt, {Craig S.} and Welkowitz, {Lawrence A.} and Juster, {Harlan R.} and Raphael Campeas and Bruch, {Monroe A.} and Marylene Cloitre and Brian Fallon and Klein, {Donald F.}",
year = "1998",
month = "12",
doi = "10.1001/archpsyc.55.12.1133",
language = "English (US)",
volume = "55",
pages = "1133--1141",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Cognitive behavioral group therapy vs phenelzine therapy for social phobia 12-week outcome

AU - Heimberg, Richard G.

AU - Liebowitz, Michael R.

AU - Hope, Debra A

AU - Schneier, Franklin R.

AU - Holt, Craig S.

AU - Welkowitz, Lawrence A.

AU - Juster, Harlan R.

AU - Campeas, Raphael

AU - Bruch, Monroe A.

AU - Cloitre, Marylene

AU - Fallon, Brian

AU - Klein, Donald F.

PY - 1998/12

Y1 - 1998/12

N2 - Background: This article presents results of the acute treatment phase of a 2-site study comparing cognitive behavioral group therapy (CBGT) and treatment with the monoamine oxidase inhibitor phenelzine sulfate for social phobia. Methods: One hundred thirty-three patients from 2 sites received 12 weeks of CBGT, phenelzine therapy, pill placebo administration, or educational-supportive group therapy (an attention-placebo treatment of equal credibility to CBGT). The 'allegiance effect,' ie, the tendency for treatments to seem most efficacious in settings of similar theoretical orientation and less efficacious in theoretically divergent settings, was also examined by comparing responses to the treatment conditions at both sites: 1 known for pharmacological treatment of anxiety disorders and the other for cognitive behavioral treatment. Results: After 12 weeks, phenelzine therapy and CBGT led to superior response rates and greater change on dimensional measures than did either control condition. However, response to phenelzine therapy was more evident after 6 weeks, and phenelzine therapy was also superior to CBGT after 12 weeks on some measures. There were few differences between sites, suggesting that these treatments can be efficacious at facilities with differing theoretical allegiances. Conclusions: After 12 weeks, both phenelzine therapy and CBGT were associated with marked positive response. Although phenelzine therapy was superior to CBGT on some measures, both were more efficacious than the control conditions. More extended cognitive behavioral treatment and the combination of modalities may enhance treatment effect.

AB - Background: This article presents results of the acute treatment phase of a 2-site study comparing cognitive behavioral group therapy (CBGT) and treatment with the monoamine oxidase inhibitor phenelzine sulfate for social phobia. Methods: One hundred thirty-three patients from 2 sites received 12 weeks of CBGT, phenelzine therapy, pill placebo administration, or educational-supportive group therapy (an attention-placebo treatment of equal credibility to CBGT). The 'allegiance effect,' ie, the tendency for treatments to seem most efficacious in settings of similar theoretical orientation and less efficacious in theoretically divergent settings, was also examined by comparing responses to the treatment conditions at both sites: 1 known for pharmacological treatment of anxiety disorders and the other for cognitive behavioral treatment. Results: After 12 weeks, phenelzine therapy and CBGT led to superior response rates and greater change on dimensional measures than did either control condition. However, response to phenelzine therapy was more evident after 6 weeks, and phenelzine therapy was also superior to CBGT after 12 weeks on some measures. There were few differences between sites, suggesting that these treatments can be efficacious at facilities with differing theoretical allegiances. Conclusions: After 12 weeks, both phenelzine therapy and CBGT were associated with marked positive response. Although phenelzine therapy was superior to CBGT on some measures, both were more efficacious than the control conditions. More extended cognitive behavioral treatment and the combination of modalities may enhance treatment effect.

UR - http://www.scopus.com/inward/record.url?scp=0031736386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031736386&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.55.12.1133

DO - 10.1001/archpsyc.55.12.1133

M3 - Article

C2 - 9862558

AN - SCOPUS:0031736386

VL - 55

SP - 1133

EP - 1141

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 12

ER -